CAS: 100910-66-5; 5-Methylnicotinaldehyde

相似化合物

29681-45-6 3222-49-9 102074-19-1

上下游产品

CAS号102074-19-1 (5-甲基吡啶-3-基)甲醇 | CAS号29681-45-6 5-甲基烟酸甲酯 | CAS号113118-75-5 phenyl 5-formyl... | CAS号3222-49-9 5-甲基烟酸 | CAS号591-22-0 3,5-二甲基吡啶 | CAS号108-99-6 3-甲基吡啶 | CAS号113118-69-7 phenyl 3-methyl...

📜3,5-二甲基吡啶置于盐酸,Potassium Permanganate,Lithium Aluminium Tetrahydride,草酰氯,二甲基亚砜,三乙胺体系中,用 乙醚,水 用作溶剂,化学反应 5.83H,反应生成5-甲基吡啶-3-甲醛
参考文献:A General Synthesis Of Substituted Fluorenones And Azafluorenones
标题:A General Synthesis Of Substituted Fluorenones And Azafluorenones
摘要:
Doi:10.1021/jo00250A019

专利信息

专利号:US-8952042-B2
优先权日:2009-08-19
标 题 :FXR (NR1H4) binding and activity modulating compounds
发明人：KREMOSER CLAUS; ABEL ULRICH; STEENECK CHRISTOPH; KINZEL OLAF
权利人:KREMOSER CLAUS; ABEL ULRICH; STEENECK CHRISTOPH; KINZEL OLAF; PHENEX PHARMACEUTICALS AG
摘要:The present invention relates to compounds of formula (1): n nwhere R, A, Q and Z are defined herein, or an enantiomer, diastereomer, tautomer, solvate, prodrug or pharmaceutical acceptable salt thereof. These compounds bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.

专利号:US-3160633-A
优先权日:1962-12-06
标 题:Synthesis of pyridine aldehydes
发明人：CISLAK FRANCIS E
权利人:REILLY TAR & CHEM CORP

专利号:US-9938258-B2
优先权日:2012-11-29
标 题:Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
发明人：BALOGLU ERKAN; SHECHTER SHARON; SHACHAM SHARON; MCCAULEY DILARA; SENAPEDIS WILLIAM; GOLAN GALI; KALID ORI
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula I: n nor a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.